8-K: Guardant Health Announces Preliminary Q4 and Full Year 2024 Results, Driven by Strong Clinical and Biopharma Growth

Guardant Health reports preliminary unaudited results for Q4 and full year 2024, highlighting a 31% increase in full-year revenue.

Summary

• Guardant Health announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
• Total revenue for the full year 2024 reached approximately $737 million, representing a 31% increase compared to the previous year.
• The company reported approximately 206,700 oncology clinical tests (excluding Shield) and approximately 40,500 biopharma tests for the full year, marking increases of 20% and 35%, respectively.
• For the fourth quarter of 2024, total revenue was approximately $200 million, a 29% increase year-over-year.
• Approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests were reported in Q4, representing increases of 24% and 16%, respectively.
• Shield screening tests numbered approximately 6,400 in Q4, generating approximately $4 million in revenue.
• Preliminary unaudited free cash flow was negative $84 million for the fourth quarter and negative $275 million for the full year 2024.
• As of December 31, 2024, Guardant Health held $944 million in cash, cash equivalents, restricted cash, and marketable debt securities.
• The company plans to report its fourth quarter and full year audited financial results in February 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and increasing test volumes, but the negative free cash flow is a concern. The sentiment is moderately positive overall.

Positives

• The company experienced strong revenue growth, driven by both clinical and biopharma segments.
• The launch of Shield saw strong traction and support in its first full quarter of commercial launch.
• Guardant Health has a substantial cash position of $944 million.
• The company completed the upgrade of Guardant360 LDT onto its Smart Liquid Biopsy platform.

Negatives

• The company reported negative free cash flow of $84 million for Q4 2024 and $275 million for the full year 2024.

Risks

• The financial results are preliminary and unaudited, subject to change upon completion of the year-end close and review procedures.
• The company's independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates.
• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results.

Future Outlook

Guardant Health believes it is well-positioned to continue driving growth in its oncology business and is focused on rapidly growing its commercial infrastructure to capture the opportunity in its screening business. The company looks forward to achieving additional milestones in 2025.

Management Comments

• '2024 was an outstanding year for Guardant. We delivered key milestones across the portfolio and completed the upgrade of Guardant360 LDT onto our Smart Liquid Biopsy platform,' said Helmy Eltoukhy, co-founder and co-CEO.
• Helmy Eltoukhy also stated, 'We finished the year strong with preliminary full year revenue growth of 31%, driven by strong clinical and biopharma revenue and increasing Guardant360 ASPs. Looking ahead, we believe we are well positioned to continue to drive growth in our oncology business.'
• AmirAli Talasaz, co-founder and co-CEO, said, 'We are extremely pleased with the strong traction and support we saw in the first full quarter of commercial launch of Shield. Given this success, we are focused on rapidly growing our commercial infrastructure to capture the massive opportunity ahead. We look forward to achieving additional milestones in 2025 as we continue driving innovation and growth in our screening business.'

Industry Context

Guardant Health's focus on liquid biopsy and precision oncology aligns with the broader industry trend towards personalized medicine and early cancer detection. The company's growth in clinical and biopharma testing reflects the increasing adoption of these technologies in cancer care and drug development.

Comparison to Industry Standards

• It is difficult to compare Guardant Health directly to other companies without knowing their specific product mix and stage of development.
• However, companies like Exact Sciences (EXAS) in the cancer screening space and Roche (RHHBY) and Illumina (ILMN) in the broader diagnostics market are relevant comparators.
• Guardant Health's 31% revenue growth is strong compared to the overall diagnostics market, but specific comparisons would require a deeper dive into peer performance.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth and increasing test volumes.
• Employees may be motivated by the company's success and future growth prospects.
• Customers (oncologists and biopharma companies) will benefit from the company's innovative products and services.
• Suppliers may see increased demand for their products and services as Guardant Health expands its operations.

Next Steps

• Guardant Health plans to report its fourth quarter and full year audited financial results in February 2025.
• The company will continue to focus on driving growth in its oncology business and expanding its commercial infrastructure for the Shield screening test.

Key Dates